IL-15-expressing chimeric antigen receptor T-cells (Shanxi Bethune Hospital)

IL-15-expressing chimeric antigen receptor T-cells (Shanxi Bethune Hospital) is an investigational autologous CAR-T cell therapy being developed for the treatment of relapsed or refractory hematological malignancies, including acute lymphocytic leukemia (ALL), non-Hodgkin lymphoma (NHL), and multiple myeloma. The therapy involves T cells genetically engineered to express a chimeric antigen receptor (CAR) alongside Interleukin-15 (IL-15). IL-15 is a potent cytokine that promotes the survival, expansion, and metabolic fitness of T cells and natural killer (NK) cells. By co-expressing IL-15, these CAR-T cells are designed to overcome common limitations such as poor persistence and exhaustion in the tumor microenvironment, potentially enhancing anti-tumor efficacy and long-term remission in patients with advanced blood cancers.

Other names

chimeric antigen receptor gene modified t cells-Shanxi Bethune Hospital-acute lymphocytic leukemia-non-Hodgkin lymphoma-multiple myelomaIL-15 co-expressing CAR-T cellsIL15 co-expressing CAR-T cellsIL 15 co-expressing CAR-T cellsNovel CAR-T combined expression of IL-15chimeric antigen receptor gene modified T cells